{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:03Z","timestamp":1792197303559,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jconrel.2024.02.018","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:25:03Z","timestamp":1707999903000},"page":"821-836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models"],"prefix":"10.1016","volume":"367","author":[{"given":"Aysha S.","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remant","family":"K.C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis C.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Nasrullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Nisakar","family":"Meenakshi Sundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Kucharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Uluda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.02.018_bb0005","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10245332.2016.1182695","article-title":"The treatment of CML at an environment with limited resources","volume":"21","author":"G\u00f3mez-Almaguer","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0010","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000473","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL study group (FILO)","volume":"4","author":"Quinquenel","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0020","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0025","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V88.7.2375.bloodjournal8872375","article-title":"The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype","volume":"88","author":"Melo","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0030","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0035","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0045","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and Epigenomic landscapes of adult De novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0050","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3747\/co.v18i2.391","article-title":"Monitoring response and resistance to treatment in chronic myeloid leukemia","volume":"18","author":"Assouline","year":"2011","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0060","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0065","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0070","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0085","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0090","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood.2020007626","article-title":"Clonal evolution of acute myeloid leukemia with FLT3 -ITD mutation under treatment with midostaurin","volume":"137","author":"Schmalbrock","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2019-122620","article-title":"Emerging mutations at relapse in patients with FLT3-mutated relapsed\/refractory acute myeloid leukemia who received Gilteritinib therapy in the phase 3 admiral trial","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-020-00964-5","article-title":"Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0105","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1038\/s41598-022-09048-5","article-title":"Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model","volume":"12","author":"Lindstr\u00f6m","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0110","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-022-00677-7","article-title":"Clinical outcomes in patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","volume":"12","author":"Perl","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0120","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.bbmt.2011.02.003","article-title":"Role of allogeneic transplantation for FLT3\/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution","volume":"17","author":"DeZern","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2991\/chi.d.190310.001","volume":"1","author":"Bazarbachi","year":"2019","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0130","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0135","doi-asserted-by":"crossref","DOI":"10.1039\/C7TB01833A","article-title":"Biomaterials for polynucleotide delivery to anchorage-independent cells","volume":"5","author":"Ansari","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2013.05.014","article-title":"Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation","volume":"172","author":"Valencia-Serna","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2019.08.018","article-title":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","volume":"310","author":"Valencia-Serna","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2015.12.052","article-title":"Targeting CXCR4\/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia","volume":"224","author":"Landry","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0160","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1089\/scd.2018.0196","article-title":"BCR-Abl silencing by siRNA: a potent approach to sensitize chronic myeloid leukemia cells to tyrosine kinase inhibitor therapy","volume":"28","author":"KC","year":"2019","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0165","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mabi.201000402","article-title":"Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers","volume":"11","author":"Aliabadi","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0170","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jbm.a.36837","article-title":"Cholesterol grafted cationic lipopolymers: potential siRNA carriers for selective chronic myeloid leukemia therapy","volume":"108","author":"Remant","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0175","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2014.08.008","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","volume":"38","author":"Gul-Uluda\u011f","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0180","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1016\/j.biomaterials.2014.07.029","article-title":"siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers","volume":"35","author":"\u015eahin","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251719","article-title":"Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL)","volume":"16","author":"Mohseni","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0190","series-title":"Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies","author":"Wu","year":"2022"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.a.37214","article-title":"Investigation of water-insoluble hydrophobic polyethylenimines as RNAi vehicles in chronic myeloid leukemia therapy","volume":"109","author":"Ansari","year":"2021","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0200","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0205","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/pharmaceutics15031009","article-title":"DLin-MC3-containing mRNA lipid nanoparticles induce an antibody Th2-biased immune response polarization in a delivery route-dependent manner in mice","volume":"15","author":"Yavuz","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0210","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1002\/ajh.23338","article-title":"Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors","volume":"87","author":"Redaelli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0215","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor Asciminib with Ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0220","doi-asserted-by":"crossref","first-page":"9606","DOI":"10.1182\/blood-2022-169828","article-title":"Select P-loop mutants in BCR::ABL1 confer moderate to high degrees of resistance to Asciminib","volume":"140","author":"Leyte-Vidal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0225","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0230","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1158\/1535-7163.MCT-21-0317","article-title":"The irreversible FLT3 inhibitor FF-10101 is active against a diversity of FLT3 inhibitor resistance mechanisms","volume":"21","author":"Ferng","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0235","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0240","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0245","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-022-01390-5","article-title":"Electrostatic anti-CD33-antibody\u2013protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia","volume":"15","author":"B\u00e4umer","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0250","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1038\/sj.onc.1210364","article-title":"The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients","volume":"26","author":"Pagano","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0255","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/pharmaceutics13060877","article-title":"Protamine-based strategies for RNA transfection","volume":"13","author":"Jarzebska","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0260","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/0883911506070816","article-title":"Characterization of protamine as a transfection accelerator for gene delivery","volume":"21","author":"Tsuchiya","year":"2006","journal-title":"J. Bioact. Compat. Polym."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0265","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12935-020-01341-5","article-title":"Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress","volume":"20","author":"Hu","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","article-title":"Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia","volume":"13","author":"Brinton","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0275","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","article-title":"Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia","volume":"25","author":"Ma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0280","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-021-00502-7","article-title":"The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML","volume":"11","author":"Qiao","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0285","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3390\/cancers12061574","article-title":"Cotargeting of XPO1 enhances the antileukemic activity of midostaurin and gilteritinib in acute myeloid leukemia","volume":"12","author":"Brinton","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A novel approach for relapsed\/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0295","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00277-019-03713-y","article-title":"Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo","volume":"98","author":"Jyotsana","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jconrel.2024.02.018_bb0300","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01854-8","article-title":"Nanoparticle-mediated targeting of the fusion gene RUNX1\/ETO in t(8;21)-positive acute myeloid leukaemia","author":"Issa","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0305","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/leu.2017.269","article-title":"RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo","volume":"32","author":"Jyotsana","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jconrel.2024.02.018_bb0310","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/cancers12102766","article-title":"Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia","volume":"12","author":"Mohanty","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:59:09Z","timestamp":1759165149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":61,"alternative-id":["S0168365924001056"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}